Marco Beckmann

Marco is an early-stage venture capitalist with a focus on identifying and nurturing disruptive technology startups. With over two decades of experience in the venture capital landscape, Marco has established himself as a strategic thinker and a trusted advisor to entrepreneurs. Throughout his career, Marco has demonstrated a keen eye for promising investment opportunities across various sectors, including nanotechnology, life sciences, blockchain, artificial intelligence and quantum computing. His ability to identify emerging trends and disruptive technologies has led to successful investments in numerous early-stage companies. Marco's track record speaks for itself, with more than 30 of his investments achieving notable exits through acquisitions or successful IPOs, representing $50 billion of aggregate value creation. Some of those early investments include Arrowhead Pharmaceuticals (Nasdaq: ARWR), NanoGram (sold to Teijin), Arryx, Inc. (sold to Haemonetics).